Assessment of the efficacy of REIC/Dkk-3 gene therapy for pancreaticobiliary carcinoma

• Project/Area Number: 17K15946
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Gastroenterology
• Research Institution: Okayama University
• Principal Investigator: Uchida Daisuke 岡山大学, 大学病院, 医員 (50749215)
• Research Collaborator: Shiraha Hidenori ; Sawahara Hiroaki ; Ohyama Atsushi ; Tanaka Emi
• Project Period (FY): 2017-04-01 – 2019-03-31
• Project Status: Completed (Fiscal Year 2018)
• Budget Amount: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000); Fiscal Year 2018: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000); Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
• Keywords: 遺伝子治療 / REIC/Dkk-3遺伝子 / 胆道癌 / 膵癌 / REIC遺伝子 / 抗癌剤耐性 / REIC/DKK3 / 胆膵癌

Outline of Final Research Achievements

REIC/Dkk-3 gene expression was decreased in various cancer cells, and overexpression of REIC/Dkk-3 gene induces cancer cell death. This novel gene therapy for prostate cancer, malignant mesothelioma, and hepatocellular carcinoma was previously reported, and clinical studies have already started. We evaluated the efficacy of this gene therapy for pancreaticobiliary cancer including drug-resistant cancer cells. Our study proved the efficacy of REIC/Dkk-3 gene therapy using adenoviral vector for pancreaticobiliary cancer cell including drug-resistant cells.

Academic Significance and Societal Importance of the Research Achievements

膵癌、胆道癌および抗癌剤耐性をもった癌に対する新たな治療法として、REIC遺伝子治療が有用である可能性を示した。すでに泌尿器癌、悪性中皮腫、肝癌に対する臨床試験が進行中であり、本研究の成果をもとにさらに対象とする癌腫が拡大されることが期待される。難治癌として知られる膵癌、胆道癌における新規治療法として期待され、その学術的意義、社会的意義は大きいと考える。

Research Products

• [Presentation] The efficacy of REIC/Dkk-3 gene therapy for cholangiocarcinoma (2018)
  • Author(s): Emi Tanaka, Daisuke Uchida, Hironari Kato, Hidenori Shiraha, Hiroyuki Okada
  • Organizer: DDW2018
  • Int'l Joint Research
• [Presentation] REIC/Dkk-3遺伝子導入における胆道癌の新規治療法開発 (2018)
  • Author(s): 田中瑛美、内田大輔、加藤博也、白羽英則、岡田裕之
  • Organizer: JDDW2018
• [Presentation] 難治性肝細胞癌に対するREIC/Dkk-3を用いた遺伝子治療 (2017)
  • Author(s): 大山淳史、澤原大明、内田大輔、白羽英則、岡田裕之
  • Organizer: 第53回肝臓学会総会
• [Presentation] 肝癌に対するREIC/DKK-3遺伝子治療 (2017)
  • Author(s): 大山淳史、白羽英則、澤原大明、内田大輔、岩室雅也、 中村進一郎、大西秀樹、桑木健志、竹内康人、和田望、 能祖一裕、岡田裕之
  • Organizer: 第16回日本肝がん分子標的研究会
• [Presentation] REIC/DKK-3 protein concentration induce the positive effect to the mortality of hepatocellular carcinoma (2017)
  • Author(s): Atsushi Ohyama, Daisuke Uchida, Hiroaki Sawahara , Hironari Kato , Hidenori Shiraha, Hiroyuki Okada
  • Organizer: UEG Week 25th
• [Presentation] Innovative therapeutic efficacy of a novel REIC/Dkk-3 expressing adenoviral vector for hepatocellular carcinoma (2017)
  • Author(s): Hiroaki Sawahara, Hidenori Shiraha, Daisuke Uchida, Hironari Kato, Atsushi Oyama, Mari Mandai, Tetsushige Mimura, Masami Watanabe, Masakiyo Sakaguchi, Takahito Yagi, Yasutomo Nasu, Hiromi Kumon, Hiroyuki Okada
  • Organizer: UEG Week 25th